EUVIMEDEUVIMED entdecken
Crossref

Radiodynamic Therapy Using 5-Aminolevulinic Acid as a New Treatment Option for Osteosarcoma: An In Vitro and In Vivo Study

Yuki Tanemura, Tomoki Nakamura, Yumi Matsuyama, Tomohito Hagi, Takahiro Iino, Masahiro Hasegawa

Anticancer Research · 2026

DOI: 10.21873/anticanres.18183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Yuki Tanemura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan. Hauptthemen laut MEDLINE: Aminolevulinic Acid, Osteosarcoma, Bone Neoplasms, Photosensitizing Agents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The antitumor effects of 5-aminolevulinic acid (5-ALA) radiodynamic therapy (RDT) have been demonstrated in vitro and in vivo in several malignancies. However, its application in bone and soft tissue sarcomas has not been sufficiently explored. In this study, we aimed to elucidate the efficacy of 5-ALA RDT in osteosarcoma cell lines. MATERIALS AND METHODS: In vitro studies utilized human (143B) and mouse (LM8) osteosarcoma cells. Cultured cells were either untreated (control) or exposed to 5-ALA (0-1,000 μg/ml) followed by X-ray irradiation (a single dose of 5 Gy). Cell viability was measured 48 h post-irradiation. Both 143B and LM8 cells were inoculated subcutaneously into the backs of BALB/c mice. Mice were assigned to untreated (control), Rx (irradiation alone), or 5-ALA RDT groups. Mice in the Rx group received X-ray irradiation (5 Gy) after macroscopic tumor formation, while those in the 5-ALA RDT group received 5-ALA (250 mg/kg) intraperitoneally, followed by 5 Gy X-ray irradiation. The mice were sacrificed 14 days after treatment, and changes in tumor volume were evaluated. RESULTS: In vitro, 5-ALA RDT treatment of osteosarcoma cells at 200, 500 and 1,000 μg/ml significantly inhibited cell proliferation at 48 h post-treatment, compared to control cells. In mice injected with osteosarcoma cells, the 5-ALA-RDT group showed a significant reduction in tumor volume compared to the control and Rx groups. No significant changes in body weight or abnormal behavior were observed. CONCLUSION: 5-ALA RDT demonstrated significant anti-tumor effects in both in vitro and in vivo osteosarcoma models. These findings suggest its potential as a therapeutic approach for osteosarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aminolevulinic AcidOsteosarcomaBone NeoplasmsPhotosensitizing AgentsAnimalsHumansCell Line, TumorMiceMice, Inbred BALB CXenograft Model Antitumor AssaysCell SurvivalCell Proliferation

Stichwörter der Autor:innen

5-aminolevulinic acidosteosarcomaprotoporphyrin IXradiodynamic therapy

Substanzen

Aminolevulinic AcidPhotosensitizing Agents

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
  • Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan tomoki66@clin.medic.mie-u.ac.jp.

Zitieren

APA

Tanemura, Y., Nakamura, T., Matsuyama, Y., Hagi, T., Iino, T., & Hasegawa, M. (2026). Radiodynamic Therapy Using 5-Aminolevulinic Acid as a New Treatment Option for Osteosarcoma: An In Vitro and In Vivo Study. Anticancer Research. https://doi.org/10.21873/anticanres.18183

Vancouver

Tanemura Y, Nakamura T, Matsuyama Y, Hagi T, Iino T, Hasegawa M. Radiodynamic Therapy Using 5-Aminolevulinic Acid as a New Treatment Option for Osteosarcoma: An In Vitro and In Vivo Study. Anticancer Research. 2026. doi:10.21873/anticanres.18183

BibTeX
@article{Tanemura2026,
  author = {Tanemura, Yuki and Nakamura, Tomoki and Matsuyama, Yumi and Hagi, Tomohito and Iino, Takahiro and Hasegawa, Masahiro},
  title = {Radiodynamic Therapy Using 5-Aminolevulinic Acid as a New Treatment Option for Osteosarcoma: An In Vitro and In Vivo Study},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18183}
}
Kostenlos starten →